APA citáció

Robak Tadeusz, Jin Jie, Pylypenko Halyna, Verhoef Gregor, Siritanaratkul Noppadol, Drach Johannes, . . . et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: Final overall survival results of a randomised, open-label, phase 3 study.

Chicago Style (17th ed.) Citation

Robak Tadeusz, et al. Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Transplantation-ineligible Patients with Newly Diagnosed Mantle Cell Lymphoma: Final Overall Survival Results of a Randomised, Open-label, Phase 3 Study. 2018.

MLA idézés

Robak Tadeusz, et al. Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Transplantation-ineligible Patients with Newly Diagnosed Mantle Cell Lymphoma: Final Overall Survival Results of a Randomised, Open-label, Phase 3 Study. 2018.